The new programme aims to increase the detection of MPM, focusing on workers at asbestos cement factories, in Portugal, who have been exposed to asbestos since the 1960’s, and covering a total of around 200 people who have already been identified by SOS Amianto.
 

This agreement, formally signed yesterday in a ceremony that took place at the Lisbon City Hall, will allow women under 50 in the city to undergo free breast cancer screenings. This initiative, set to be implemented by the end of the year, aims to tackle the alarming rise in cancer incidence among younger women.

The Champalimaud Foundation, a private non-profit research institution located in Lisbon, Portugal, has achieved a significant milestone in cancer research and pre-clinical development by obtaining exclusive rights to deploy synthetic biology technologies initially licensed from Stanford University and further developed by Refuge Biotechnologies (Refuge), a pioneering synthetic biology company specialising in cancer immunotherapy.

A novel infrastructure for storing, consulting and analysing medical data will be presented at the Open Day of the Champalimaud Foundation (FC) Breast Unit, which is taking place today, October 16. It was created by the Unit's Digital Surgery Lab, a multidisciplinary team led by surgeon Pedro Gouveia, in partnership with the telecommunications company Altice and the Portuguese company BMD Software.

Understanding Treatment-Resistant Depression

Treatment-resistant depression (TRD) is a particularly challenging form of major depressive disorder. As Albino Oliveira-Maia, head of the Champalimaud Foundation’s Neuropsychiatry Unit and the study’s national coordinator for Portugal, explains, “TRD is defined as the persistence of depressive symptoms despite adequate courses of at least two different antidepressant medications”. Despite repeated therapeutic attempts, these patients’ depressive symptoms remain.

The Breast Unit of the Champalimaud Clinical Center organizes, for the 5th year, the Breast Unit Open Day, this year dedicated to Artificial Intelligence and its transformative impact on breast cancer patients.

A side-effect “is any effect of a drug, chemical, or other medicine that is in addition to its intended effect, especially an effect that is harmful or unpleasant”. 

Malignant melanoma is a highly aggressive form of skin cancer that is on the rise. However, recent breakthrough research has introduced new targeted therapies and immunotherapies for melanoma treatment, transforming the approach to treating melanoma and offering hope to patients with limited alternatives.

In the midst of a territory that has long been a hotspot for armed confrontation and humanitarian instability, the St John of Jerusalem Eye Hospital Group (SJEHG) has managed to provide top quality eye care, as well as ophthalmic training to local medical professionals. 

“For its commitment to providing essential eye care in a region marked by conflict”, the Group has now been recognized with the one-million-euro 2023 António Champalimaud Vision Award, the Champalimaud Foundation announced in a statement.